{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:44:27Z","timestamp":1792453467831,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.neurot.2026.e00861","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T19:30:01Z","timestamp":1773343801000},"page":"e00861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patients"],"prefix":"10.1016","volume":"23","author":[{"given":"Ghida","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Zeineddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Al-Roughani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar Farouk","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Al-Mahdawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"El-Ayoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihad","family":"Inshasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaber","family":"Al-Khabouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Al-Asmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riadh","family":"Gouider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Aljarallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuha","family":"Alkhawajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser","family":"Al Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Abulaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seraj","family":"Makkawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Khojah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taghrid","family":"El-Hajj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Massouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam","family":"AlSalamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Al-Hajje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Salameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Boumediene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Yamout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2026.e00861_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuron.2006.09.011","article-title":"The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration","volume":"52","author":"Hauser","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2026.e00861_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2026.e00861_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ana.21079","article-title":"Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial","volume":"61","author":"Wolinsky","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2026.e00861_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jneuroim.2006.07.006","article-title":"Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness","volume":"180","author":"Link","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurot.2026.e00861_bib5","first-page":"2782","article-title":"Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients","volume":"164","author":"Colombo","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.neurot.2026.e00861_bib6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: a regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/j.neurot.2026.e00861_bib7","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurot.2026.e00861_bib8","doi-asserted-by":"crossref","first-page":"e1805","DOI":"10.1212\/WNL.0000000000005516","article-title":"Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study","volume":"90","author":"Bar-Or","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2026.e00861_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e00861_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e00861_bib11","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209610","article-title":"Efficacy of ofatumumab and teriflunomide in patients with relapsing MS from racial\/ethnic minority groups: ASCLEPIOS I\/II subgroup analyses","volume":"103","author":"Williams","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2026.e00861_bib12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1042\/bst0250705","article-title":"Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin\u2019s B-cell lymphoma","volume":"25","author":"Anderson","year":"1997","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.neurot.2026.e00861_bib13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e00861_bib14","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2026.e00861_bib15","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.neurot.2026.e00861_bib16","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1177\/13524585211030207","article-title":"Ethical use of off-label disease-modifying therapies for multiple sclerosis","volume":"27","author":"Laurson-Doube","year":"2021","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"10.1016\/j.neurot.2026.e00861_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104959","article-title":"Barriers to accessing multiple sclerosis disease-modifying therapies in the Middle East and North Africa region: a regional survey-based study","volume":"79","author":"Zeineddine","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2026.e00861_bib19","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2026.e00861_bib20","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/brain\/aww173","article-title":"Defining secondary progressive multiple sclerosis","volume":"139","author":"Lorscheider","year":"2016","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurot.2026.e00861_bib21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1749-6632.1965.tb20235.x","article-title":"Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis","volume":"122","author":"Schumacher","year":"1965","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.neurot.2026.e00861_bib22","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1007\/s12325-020-01367-1","article-title":"Treatment patterns among patients with multiple sclerosis initiating second-line disease-modifying therapy","volume":"37","author":"Bowen","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.neurot.2026.e00861_bib23","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1177\/1352458517709619","article-title":"Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study","volume":"24","author":"Kappos","year":"2018","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"10.1016\/j.neurot.2026.e00861_bib24","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s40120-023-00549-7","article-title":"No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]","volume":"12","author":"Newsome","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.neurot.2026.e00861_bib25","series-title":"Resources for researchers: common terminology criteria for adverse events (CTCAE)","year":"2018"},{"key":"10.1016\/j.neurot.2026.e00861_bib26","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2026.e00861_bib27","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2026.e00861_bib28","article-title":"Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis - a cohort study","volume":"7","author":"Torgauten","year":"2021","journal-title":"Mult Scler J - Exp Transl Clin"},{"key":"10.1016\/j.neurot.2026.e00861_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9084759","article-title":"Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study","volume":"2018","author":"Yamout","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.neurot.2026.e00861_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197415","article-title":"Effectiveness and safety of rituximab in multiple sclerosis: an observational study from Southern Switzerland","volume":"13","author":"Scotti","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2026.e00861_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/11585960-000000000-00000","article-title":"Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre","volume":"34","author":"Brown","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.neurot.2026.e00861_bib32","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2026.e00861_bib33","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with Fingolimod, Natalizumab, Rituximab, and Injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2026.e00861_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-008142","article-title":"Progressive multifocal leukoencephalopathy during treatment with rituximab and CHOP chemotherapy in a patient with a diffuse large B-cell lymphoma","volume":"2013","author":"Sikkema","year":"2013","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.neurot.2026.e00861_bib35","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/0961203315622819","article-title":"Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review","volume":"25","author":"Henegar","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.neurot.2026.e00861_bib36","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1212\/CPJ.0000000000000202","article-title":"PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents","volume":"6","author":"Kanth","year":"2016","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.neurot.2026.e00861_bib37","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1177\/1352458518786075","article-title":"Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients","volume":"25","author":"Oshima","year":"2019","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"10.1016\/j.neurot.2026.e00861_bib38","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden","volume":"177","author":"Wadstr\u00f6m","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.neurot.2026.e00861_bib39","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/ana.25701","article-title":"Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients","volume":"87","author":"Alping","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2026.e00861_bib40","article-title":"Potential impact of B cells on T cell function in multiple sclerosis","volume":"2011","author":"Ireland","year":"2011","journal-title":"Mult Scler Int"},{"key":"10.1016\/j.neurot.2026.e00861_bib41","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000498","article-title":"Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders","volume":"5","author":"Marcinn\u00f2","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurot.2026.e00861_bib42","article-title":"Extended-interval dosing of rituximab\/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosis","volume":"22","author":"Rigollet","year":"2025","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"10.1016\/j.neurot.2026.e00861_bib43","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections","volume":"11","author":"Langer-Gould","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurot.2026.e00861_bib44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"269","author":"Chisari","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2026.e00861_bib45","first-page":"527","article-title":"Budget impact analysis of switching to rituximab's biosimilar in rheumatology and cancer in 13 countries within the Middle East and North Africa","volume":"12","author":"Almaaytah","year":"2020","journal-title":"Clin Outcomes Res CEOR"},{"key":"10.1016\/j.neurot.2026.e00861_bib46","article-title":"Treatment of multiple sclerosis in special populations: the case of refugees","volume":"6","author":"Zeineddine","year":"2020","journal-title":"Mult Scler J - Exp Transl Clin"},{"key":"10.1016\/j.neurot.2026.e00861_bib47","unstructured":"Public consultation now closed: guidelines for the use of off-label azathioprine and rituximab for the treatment of MS in low-resource settings. MS Int Fed n.d. https:\/\/www.msif.org\/molt-guidelines-azathioprine-rituximab\/(accessed April 28, 2025)."},{"key":"10.1016\/j.neurot.2026.e00861_bib48","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200056","article-title":"Sustained low relapse rate with highly variable B-Cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis","volume":"10","author":"Starvaggi Cucuzza","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurot.2026.e00861_bib49","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000825","article-title":"Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?","volume":"7","author":"Maarouf","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurot.2026.e00861_bib50","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200152","article-title":"Efficacy of rituximab outlasts B-Cell repopulation in multiple sclerosis: time to rethink dosing?","volume":"10","author":"Claverie","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflammation"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:04:47Z","timestamp":1781640287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926000310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1878747926000310"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00861","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00861","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00861"}}